Pharma partnership to improve clinical trial communication

To better connect patients and researchers, three pharmaceutical companies are partnering with clinicaltrials.gov on a new platform to improve access to information about clinical trials.

More than half of Americans say they would be interested in participating in a clinical trial but almost half of all studies never reach their recruitment targets.

To address the problem, Novartis, Pfizer and Eli Lilly are collaborating on a platform that will enhance clinicaltrials.gov and provide more detailed and patient-friendly information about trials, including a machine readable “target health profile” to improve the ability of healthcare software to match individual health profiles to applicable clinical trials.

Additionally, patients can search for trials themselves using their own Blue Button data.

The platform launch is planned for early 2014 with a starting database of about 50 clinical research studies from the participating companies. The platform will be open on both ends, allowing other sponsors of clinical research studies to upload information about their trials, while software companies develop tools to deliver information to interested patients.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.